Antibiotikaprofylax vid kirurgiska ingrepp - SBU

Table 4.12.4 continued
Author
Year
Reference
Country
Study
design
Population
characteristics
Intervention
Method
Number individuals
Control
Number
individuals
Results
Withdrawal
Drop outs
Study quality
and relevance
Comments
Puig
2006
[16]
Spain
Casecontrol
Transrectal prostate
core biopsy. No history
of prior UTI or prostatitis.
n=1 018
I: ABP in second cohort
of 404 men
C: No ABP in
first cohort
of 614 men
(historical
controls)
Minor infectious complications
I: 5/404 (1.2%)
C: 32/614 (5.2%)
Major infectious complications
I: 10/404 (2.5%)
C: 31/614 (5.0%)
ABP significantly reduce
infectious complications,
both major and minor.
RR of infection in ABP group
=0.36 and NNT 15.3
No
relevant
High
Minor infectious
complications =
symptomatic UTI,
prostatitis, epidydimitis
requiring
no hospitalisation
Major infectious
complications =
requiring hospitalisation
(febrile
UTI, sepsis).
Overall infectious
complications=7.6%
Sabbagh
2004
[27]
Canada
RCT
Transrectal core prostate
biopsy. No exclusion
criteria
I: 2 doses ciprofloxacin
500 mg first day or single
dose levofloxacin 500 mg
(n=181)
C: 2 doses ciprofloxacin
500 mg
for 3 days or levofloxacin
500 mg
one dose for
3 days (n=182)
Infective complication
I: 1 sepsis (endocarditis).
No symptomatic UTI
C: 1 sepsis.
No symptomatic UTI
Moderate
One day ABP
with a quinolone
as effective as
3 days
Schaeffer
2007
[28]
USA
RCT Core prostate biopsy I: 1-day regimen
ciprofloxacin (n=247)
C: 3-day regimen
dito (n=250)
Bacteriological success
I: 199/210 (95%)
C: 197/201 (98%) ns
Clinical efficacy
I: 203/210 (96.7)
C: 198/201 (98.5) ns
32 (7%) High
Febrile UTI 2.9%.
No difference
1 or 3 days
The table continues on the next page
460 antibiotikaprofylax vid kirurgiska ingrepp KAPITEL 4 • den systematiska litteraturöversikten
461